A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
2 other identifiers
interventional
210
15 countries
120
Brief Summary
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Jun 2025
120 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 14, 2025
CompletedFirst Posted
Study publicly available on registry
June 12, 2025
CompletedStudy Start
First participant enrolled
June 19, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2027
April 22, 2026
April 1, 2026
1.9 years
May 14, 2025
April 21, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of participants who are euthyroid and off ATD at Week 26 (Dose 1)
Week 26
Secondary Outcomes (9)
Percentage of participants who have triiodothyronine (T3) (Total of T3 or free triiodothyronine [FT3]) and free thyroxine (FT4) ≤ upper limit of normal (ULN) and are off ATD at Week 26 (Dose 1)
Week 26
Percentage of participants who are euthyroid, off ATD, and seronegative at Week 26 (Dose 1)
Week 26
Percentage of participants who are euthyroid and off ATD at Week 26 (Dose 2)
Week 26
Percentage of participants who have T3 (Total T3 or FT3) and FT4 ≤ ULN and are off ATD at Week 26 (Dose 2)
Week 26
Percentage of participants who are euthyroid, off ATD, and seronegative (Dose 2)
Week 26
- +4 more secondary outcomes
Study Arms (3)
IMVT-1402 Dose 1
EXPERIMENTALIMVT-1402 Dose 2
EXPERIMENTALPlacebo
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.
- Male or female participants aged ≥ 18 years.
- Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.
You may not qualify if:
- Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy.
- Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk.
- Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (120)
Site Number - 1015
Tucson, Arizona, 85710, United States
Site Number -1014
Concord, California, 94520, United States
Site Number - 1013
Aurora, Colorado, 80045, United States
Site Number - 1024
Doral, Florida, 33166, United States
Site Number - 1008
Hialeah, Florida, 33016, United States
Site Number - 1000
Miami, Florida, 33143, United States
Site Number - 1020
Columbus, Georgia, 31904, United States
Site Number - 1022
Topeka, Kansas, 66606, United States
Site Number - 1030
Louisville, Kentucky, 40202, United States
Site Number - 1033
Jefferson City, Missouri, 65109, United States
Site Number - 1004
Kansas City, Missouri, 64110, United States
Site Number - 1019
St Louis, Missouri, 63110, United States
Site Number - 1012
Reno, Nevada, 89511, United States
Site Number - 1032
Long Island City, New York, 11106, United States
Site Number - 1027
New Hyde Park, New York, 11434, United States
Site Number - 1009
New York, New York, 10022, United States
Site Number - 1018
Williamsville, New York, 14221, United States
Site Number - 1010
Chapel Hill, North Carolina, 27514, United States
Site Number - 1026
Hickory, North Carolina, 28601, United States
Site Number - 1001
Morehead City, North Carolina, 27577, United States
Site Number - 1034
Raleigh, North Carolina, 27612, United States
Site Number - 1007
Oklahoma City, Oklahoma, 73134, United States
Site Number - 1017
Memphis, Tennessee, 38119, United States
Site Number - 1029
Dallas, Texas, 75224, United States
Site Number - 1002
El Paso, Texas, 79935, United States
Site Number - 1003
Fort Worth, Texas, 76132, United States
Site Number - 1031
Houston, Texas, 77030, United States
Site Number - 1028
Houston, Texas, 77054, United States
Site Number -1023
Irving, Texas, 75031, United States
Site Number - 1021
Irving, Texas, 75039, United States
Site Number - 1025
McKinney, Texas, 75069, United States
Site Number - 1011
San Antonio, Texas, 78231, United States
Site Number - 1016
Norfolk, Virginia, 23510, United States
Site Number - 5105
Sydney, New South Wales, 2050, Australia
Site Number - 5103
Warrawong, New South Wales, 2502, Australia
Site Number - 5101
Brisbane, Queensland, 4101, Australia
Site Number - 5107
Douglas, Queensland, 4814, Australia
Site Number - 5100
Southport, Queensland, 4222, Australia
Site Number - 5102
Box Hill, Victoria, 3128, Australia
Site Number - 5104
Geelong, Victoria, 3220, Australia
Site Number - 5108
Perth, 6009, Australia
Site Number - 5109
Saint Leonards, 2065, Australia
Site Number - 5505
Santo André, São Paulo, 09060-870, Brazil
Site Number - 5610
Sofia, Sofia-Grad, 1431, Bulgaria
Site Number - 5613
Dobrich, 7002, Bulgaria
Site Number - 5606
Plovdiv, 4001, Bulgaria
Site Number - 5607
Plovdiv, 4002, Bulgaria
Site Number - 5601
Sliven, 8800, Bulgaria
Site Number - 5612
Smolyan, 4700, Bulgaria
Site Number - 5604
Sofia, 1233, Bulgaria
Site Number - 5609
Sofia, 1431, Bulgaria
Site Number - 5608
Sofia, 1680, Bulgaria
Site Number- 5605
Sofia, 1750, Bulgaria
Site Number - 5602
Varna, 9002, Bulgaria
Site Number - 5603
Varna, 9020, Bulgaria
Site Number - 5611
Varna, 9020, Bulgaria
Site Number - 5600
Yambol, 8600, Bulgaria
Site Number - 3203
Náchod, 547 01, Czechia
Site Number - 3201
Prague, 149 00, Czechia
Site Number - 3200
Prague, 181 00, Czechia
Site Number - 3202
Prague, 190 14, Czechia
Site Number - 8004
Imereti, 4600, Georgia
Site Number - 8003
Tbilisi, 0114, Georgia
Site Number - 8000
Tbilisi, 0145, Georgia
Site Number - 8002
Tbilisi, 0159, Georgia
Site Number - 8001
Tbilisi, 0160, Georgia
Site Number - 8005
Tbilisi, 0186, Georgia
Site Number - 3902
Athens, 106 76, Greece
Site Number - 3900
Athens, 115 27, Greece
Site Number - 3901
Athens, 115 28, Greece
Site Number - 4202
Ramat Gan, Central District, 5265601, Israel
Site Number - 4205
Haifa, Haifa District, 3104802, Israel
Site Number - 4203
Haifa, Haifa District, 3109601, Israel
Site Number - 4209
Nahariya, Northern District, 2210001, Israel
Site Number - 4206
Tzfat, Northern District, 1311001, Israel
Site Number - 4211
Beersheba, Southern District, 8410101, Israel
Site Number - 4201
Jerusalem, 9103102, Israel
Site Number - 4204
Jerusalem, 9112001, Israel
Site Number - 4210
Kfar Saba, 4428164, Israel
Site Number - 4200
Petah Tikva, 4941492, Israel
Site Number - 4208
Rehovot, 7661041, Israel
Site Number - 4207
Tel Aviv, 6423906, Israel
Site Number - 6005
Rozzano, Milan, 20089, Italy
Site Number - 6003
Milan, 20132, Italy
Site Number - 6006
Pavia, 27100, Italy
Site Number - 6001
Rome, 135, Italy
Site Number - 6002
Udine, 33100, Italy
Site Number - 4600
Ogre, LV-5001, Latvia
Site Number - 4602
Riga, LV-1006, Latvia
Site Number - 4603
Riga, LV-1050, Latvia
Site Number - 4604
Sigulda, LV-2150, Latvia
Site Number - 4601
Ventspils, LV-3601, Latvia
Site Number - 2003
Rotterdam, South Holland, 3045 PM, Netherlands
Site Number - 2200
Rotterdam, South Holland, 3079 DZ, Netherlands
Site Number - 2201
Rotterdam, South Holland, 3083 AN, Netherlands
Site Number - 2202
Zwijndrecht, South Holland, 3318 AT, Netherlands
Site Number - 3301
Auckland, 2025, New Zealand
Site Number - 3300
Wellington, 6242, New Zealand
Site Number - 3004
Bialystok, Podlaskie Voivodeship, 15-276, Poland
Site Number - 3001
Szczecin, West Pomeranian Voivodeship, 71-252, Poland
Site Number - 3002
Bydgoszcz, 85-605, Poland
Site Number - 3010
Chorzów, 41-516, Poland
Site Number - 3007
Kielce, 25-734, Poland
Site Number - 3000
Lublin, 20-607, Poland
Site Number - 3005
Olsztyn, 10-117, Poland
Site Number - 3009
Opole, 45-301, Poland
Site Number - 3006
Poznan, 60-693, Poland
Site Number - 3008
Warsaw, 02-482, Poland
Site Nnumber - 3003
Wroclaw, 50-367, Poland
Site Number - 4500
Daegu, 42415, South Korea
Site Number - 4503
Goyang, 410-77, South Korea
Site Number - 4504
Guri-si, 11923, South Korea
Site Number - 4501
Seoul, 02841, South Korea
Site Number - 4506
Seoul, 03181, South Korea
Site Number - 4505
Seoul, 05278, South Korea
Site Number - 7009
Cornwell, TR1 3LJ, United Kingdom
Site Number - 7006
London, SE1 9RT, United Kingdom
Site Number - 7001
London, W2 1NY, United Kingdom
Site Number - 7010
Salford, M6 8HD, United Kingdom
Site Number - 7008
Surrey, GU2 7XX, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 14, 2025
First Posted
June 12, 2025
Study Start
June 19, 2025
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
May 1, 2027
Last Updated
April 22, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share